350 related articles for article (PubMed ID: 16740863)
1. Longitudinal changes of brain-type natriuretic peptide in preterm neonates.
da Graca RL; Hassinger DC; Flynn PA; Sison CP; Nesin M; Auld PA
Pediatrics; 2006 Jun; 117(6):2183-9. PubMed ID: 16740863
[TBL] [Abstract][Full Text] [Related]
2. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates.
Sanjeev S; Pettersen M; Lua J; Thomas R; Shankaran S; L'Ecuyer T
J Perinatol; 2005 Nov; 25(11):709-13. PubMed ID: 16222347
[TBL] [Abstract][Full Text] [Related]
3. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus.
Farombi-Oghuvbu I; Matthews T; Mayne PD; Guerin H; Corcoran JD
Arch Dis Child Fetal Neonatal Ed; 2008 Jul; 93(4):F257-60. PubMed ID: 18218660
[TBL] [Abstract][Full Text] [Related]
4. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates.
Flynn PA; da Graca RL; Auld PA; Nesin M; Kleinman CS
J Pediatr; 2005 Jul; 147(1):38-42. PubMed ID: 16027692
[TBL] [Abstract][Full Text] [Related]
5. Early N-terminal pro-brain natriuretic peptide measurements predict clinically significant ductus arteriosus in preterm infants.
Ramakrishnan S; Heung YM; Round J; Morris TP; Collinson P; Williams AF
Acta Paediatr; 2009 Aug; 98(8):1254-9. PubMed ID: 19432837
[TBL] [Abstract][Full Text] [Related]
6. Consequences of delayed surgical closure of patent ductus arteriosus in very premature infants.
Jaillard S; Larrue B; Rakza T; Magnenant E; Warembourg H; Storme L
Ann Thorac Surg; 2006 Jan; 81(1):231-4. PubMed ID: 16368371
[TBL] [Abstract][Full Text] [Related]
7. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants.
Choi BM; Lee KH; Eun BL; Yoo KH; Hong YS; Son CS; Lee JW
Pediatrics; 2005 Mar; 115(3):e255-61. PubMed ID: 15687418
[TBL] [Abstract][Full Text] [Related]
8. B-type and N-terminal pro-B-type natriuretic peptides are equally useful in assessing patent ductus arteriosus in very preterm infants.
König K; Guy KJ; Drew SM; Barfield CP
Acta Paediatr; 2015 Apr; 104(4):e139-42. PubMed ID: 25488470
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting N-terminal pro-B-type natriuretic peptide levels in preterm infants and use in determination of haemodynamic significance of patent ductus arteriosus.
Harris SL; More K; Dixon B; Troughton R; Pemberton C; Horwood J; Ellis N; Austin N
Eur J Pediatr; 2018 Apr; 177(4):521-532. PubMed ID: 29352349
[TBL] [Abstract][Full Text] [Related]
10. N-terminal-pro-brain natriuretic peptide: a guide for early targeted indomethacin therapy for patent ductus arteriosus in preterm Infants.
Nuntnarumit P; Chongkongkiat P; Khositseth A
Acta Paediatr; 2011 Sep; 100(9):1217-21. PubMed ID: 21457304
[TBL] [Abstract][Full Text] [Related]
11. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants.
Noori S; McCoy M; Friedlich P; Bright B; Gottipati V; Seri I; Sekar K
Pediatrics; 2009 Jan; 123(1):e138-44. PubMed ID: 19117835
[TBL] [Abstract][Full Text] [Related]
12. The effect of ductal diameter on surgical and medical closure of patent ductus arteriosus in preterm neonates: size matters.
Tschuppert S; Doell C; Arlettaz-Mieth R; Baenziger O; Rousson V; Balmer C; Prêtre R; Dodge-Khatami A
J Thorac Cardiovasc Surg; 2008 Jan; 135(1):78-82. PubMed ID: 18179922
[TBL] [Abstract][Full Text] [Related]
13. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus.
Attridge JT; Kaufman DA; Lim DS
Arch Dis Child Fetal Neonatal Ed; 2009 May; 94(3):F178-82. PubMed ID: 18981033
[TBL] [Abstract][Full Text] [Related]
14. Incidence and clinical features of patent ductus arteriosus in low-birthweight infants: a prospective analysis of 150 consecutively born infants.
Siassi B; Blanco C; Cabal LA; Coran AG
Pediatrics; 1976 Mar; 57(3):347-51. PubMed ID: 1256945
[TBL] [Abstract][Full Text] [Related]
15. Serum brain natriuretic peptide for prediction of successful medical treatment of patent ductus arteriosus in premature infants.
Ohashi A; Kaneko K
J Thorac Cardiovasc Surg; 2009 Jul; 138(1):261-2. PubMed ID: 19577111
[No Abstract] [Full Text] [Related]
16. Plasma C-terminal pro-endothelin-1 and the natriuretic pro-peptides NT-proBNP and MR-proANP in very preterm infants with patent ductus arteriosus.
Letzner J; Berger F; Schwabe S; Benzing J; Morgenthaler NG; Bucher HU; Bührer C; Arlettaz R; Wellmann S
Neonatology; 2012; 101(2):116-24. PubMed ID: 21952518
[TBL] [Abstract][Full Text] [Related]
17. [Value of amino-terminal pro-brain natriuretic peptide as a predictive marker of symptomatic patent ductus arteriosus in preterm infants].
Lu KS; Guo XL; Lv JF; Huang SL; Yang CH; Zou ZH; Chen ZJ; Lai CH; Yang BY
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Nov; 17(11):1160-4. PubMed ID: 26575871
[TBL] [Abstract][Full Text] [Related]
18. Correlation analysis between echocardiographic flow pattern and N-terminal-pro-brain natriuretic peptide for early targeted treatment of patent ductus arteriosus.
Occhipinti F; De Carolis MP; De Rosa G; Bersani I; Lacerenza S; Cota F; Rubortone SA; Romagnoli C
J Matern Fetal Neonatal Med; 2014 Nov; 27(17):1800-4. PubMed ID: 24397409
[TBL] [Abstract][Full Text] [Related]
19. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus.
Van Overmeire B; Touw D; Schepens PJ; Kearns GL; van den Anker JN
Clin Pharmacol Ther; 2001 Oct; 70(4):336-43. PubMed ID: 11673749
[TBL] [Abstract][Full Text] [Related]
20. Circulating prostaglandin E2 concentrations and incidence of patent ductus arteriosus in preterm infants with respiratory distress syndrome.
Clyman RI; Brett C; Mauray F
Pediatrics; 1980 Nov; 66(5):725-9. PubMed ID: 7432878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
